Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV000508582 | SCV000603529 | pathogenic | not specified | 2017-03-06 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV002247318 | SCV002519684 | pathogenic | Thrombophilia, X-linked, due to factor 8 defect | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000508582 | SCV005422762 | uncertain significance | not specified | 2024-10-17 | criteria provided, single submitter | clinical testing | Variant summary: F8 c.323A>C (p.Lys108Thr) results in a non-conservative amino acid change located in the Multicopper oxidase-like, N-terminal domain (IPR011707) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183423 control chromosomes. c.323A>C has been reported in the literature in the presumed hemizygous state in at least 1 individuals affected with clinical features of Factor VIII Deficiency (Hemophilia A) (example, Higuchi_1991). These data do not allow any conclusion about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in 10%-<30% of FVIII activity (example, Higuchi_1991). The following publication has been ascertained in the context of this evaluation (PMID: 1908096). ClinVar contains an entry for this variant (Variation ID: 10167). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
OMIM | RCV000010880 | SCV000031107 | pathogenic | Hereditary factor VIII deficiency disease | 1991-08-15 | no assertion criteria provided | literature only |